Summit Therapeutics (SMMT) Payables (2018 - 2026)

Summit Therapeutics (SMMT) has reported Payables for 9 consecutive years, with $22.9 million the latest figure, recorded in Q2 2026.

• Quarterly Payables changed 0.37% year-over-year to $22.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.9 million (changed 0.37% YoY) and the FY2025 annual result came in at $20.3 million, up 337.7% from the prior year.
• Payables declined to $22.9 million in Q2 2026 per SMMT's latest filing, from $27.5 million in the prior quarter.
• Over the last five years, Payables for SMMT reached as high as $103.3 million in Q2 2024 and fell as low as $710000.0 in Q1 2023.
• A 5-year average of $22.4 million and a median of $13.5 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables tumbled 89.8% — and 2024, when it soared 10370.11%.
• Year by year, Payables stood at $20.1 million in 2022, then tumbled by 86.75% to $2.7 million in 2023, then surged by 73.83% to $4.6 million in 2024, then jumped by 337.7% to $20.3 million in 2025, then advanced by 12.83% to $22.9 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $22.9 million, $27.5 million, and $20.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.